REGENERON PHARMACEUTICALS, INC.

For the period ended Jun 30, 2025. Filed Aug 1, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 1, 2025

REGN$916.06-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)

(In millions, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Statements of Operations
Revenues:
Net product sales	$1,631.0	$1,918.6	$3,046.6	$3,679.9
Collaboration revenue	1,860.7	1,524.0	3,391.9	2,790.8
Other revenue	183.9	104.5	265.8	221.4
	3,675.6	3,547.1	6,704.3	6,692.1
Expenses:
Research and development	1,421.7	1,200.0	2,749.1	2,448.4
Acquired in-process research and development	10.0	23.9	22.3	31.0
Selling, general, and administrative	634.2	758.8	1,267.2	1,447.8
Cost of goods sold	275.6	257.8	541.1	498.2
Cost of collaboration and contract manufacturing	254.6	222.4	453.4	415.8
Other operating expense (income), net	—	14.6	—	29.9
	2,596.1	2,477.5	5,033.1	4,871.1
Income from operations	1,079.5	1,069.6	1,671.2	1,821.0
Other income (expense):
Other income (expense), net	442.8	573.3	764.8	538.7
Interest expense	(3.6)	(14.8)	(12.3)	(30.9)
	439.2	558.5	752.5	507.8
Income before income taxes	1,518.7	1,628.1	2,423.7	2,328.8
Income tax expense	127.1	195.8	223.4	174.5
Net income	$1,391.6	$1,432.3	$2,200.3	$2,154.3
Net income per share - basic	$13.24	$13.25	$20.78	$19.95
Net income per share - diluted	$12.81	$12.41	$20.02	$18.68
Weighted average shares outstanding - basic	105.1	108.1	105.9	108.0
Weighted average shares outstanding - diluted	108.6	115.4	109.9	115.3
Statements of Comprehensive Income
Net income	$1,391.6	$1,432.3	$2,200.3	$2,154.3
Other comprehensive income (loss), net of tax:
Unrealized gain on debt securities	22.1	7.9	60.2	11.4
Gain (loss) on foreign currency translation	1.3	(0.6)	0.2	(0.4)
Comprehensive income	$1,415.0	$1,439.6	$2,260.7	$2,165.3
The accompanying notes are an integral part of the financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.